KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.

Cell Commun Signal · 2024 · PMC11167791 · PMID 38867255

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The cohort with high KRAS expression showed a trend towards worse progression-free survival, and overall survival was significantly worse in this cohort (Supplementary Fig. 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.